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1. INTRODUCTION 
Diabetes mellitus was first reported in Egyptian manuscript about 3000 years 
ago. In 1936, the distinction between type 1 and type II DM was clearly made. Type II 
DM was first described as a component of metabolic syndrome in 1988.1 
Type II diabetes (formerly known as non-insulin dependent DM) is due to 
insufficient insulin production from beta cells in the setting of insulin resistance.2 
Insulin resistance, which is the inability of cells to respond adequately to normal levels 
of insulin, occurs primarily within the muscles, liver, and fat tissue. In the liver, insulin 
normally suppresses glucose release.3 
The prevalence of Type II Diabetes Mellitus (DM) is increasing all over the 
world, especially in South Asia. India has largest population of diabetic patients. The 
International Diabetes Federation (IDF) estimates the number of people with diabetes 
in India will reach 80 million by the year 2025.4 
MANAGEMENT OF TYPE II DIABETES MELLITUS 
Pharmacological agents: 
There are at least seven different classes of agents used as monotherapy, or in 
combinations for the treatment of diabetes mellitus. Treatment include Metformin, 
Sulphonylureas,Meglitinides, Alpha-glucosidase inhibitors, Thiazolidinediones (TZD), 
DPP-4 inhibitors and insulin. Many conventional agents frequently exhibit reduced 
efficacy over time, leading to inadequate glycaemic control.  
Metformin was recommended by most guidelines as first line therapy for 
T2DM. However, due to the progressive nature of T2DM, inevitable combination 
therapies are often required if glycemic targets not to be maintained by metformin 
monotherapy. Insulin resistance and pancreatic cell dysfunction are the two main 
pathophysiological reasons of T2DM, hence, proper treatment for such disease should 
target both these defects. 
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Figure 1: Treatment Algorithm for Type II Diabetes Mellitus 
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GLIPTIN: DPP-4 INHIBITORS 
Dipeptidyl peptidase 4 (DPP-4) inhibitor is a relatively new class of 
antihyperglycemic agents that are now recommended as first or second-line agents in 
treatment of diabetes by guidelines like American Diabetes Association (ADA) 2016 
and American Association of Clinical Endocrinologists and American College of 
Endocrinology 2016.  
DPP-4 inhibitors control fasting plasma glucose (FPG) and postprandial plasma 
glucose (PPG) levels through selective inhibition of DPP-4, resulting in increased 
plasma concentrations of active glucagon-like peptide-1. 
DPP-4 inhibitors unlike Sulfonylureas, Meglitinides, or insulin are weight 
neutral and no risk of hypoglycemia. DPP-4 inhibitors, selectively inhibit the DPP-4 
enzyme that degrades two major incretin hormones: GIP (gastric inhibitory 
polypeptide) and GLP-1(glucagon -like peptide1). 
They are reported to have glucose lowering efficacy, without the risk of 
hypoglycemia, when added to the treatment regimen of patients in whom metformin 
monotherapy is no longer sufficient or when initial dual therapy metformin is required. 
DPP-4 inhibitors are reported to be well tolerated and efficacious in diverse population 
with type II DM including the elderly patient with renal impairment.5 
There are 11 different compounds of DPP‑ 4Is have been made available 
worldwide, of which mostly available in Japan. In India, 4 DPP‑ 4Is are already 
available and marketed that includes Sitagliptin, Vildagliptin, Saxagliptin, and 
Linagliptin. Recently, two newer molecule Teneligliptin and Gemigliptin have been 
added to this segment.  
Importantly, teneligliptin has been already approved and marketed product in 
Japan since 2012 and in Korea since 2014.  
However, teneligliptin is neither approved in the USA or in Europe although it 
was registered in the US Food and Drug Administration (FDA) for Phase 1 clinical 
development in 2007 and Phase II clinical developments in European Medicines 
Agency in 2009, without any further progress. 
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Although various DPP-4 inhibitors have different pharmacokinetic and 
Pharmacodynamic profiles, they are remarkably similar with regards anti-
hyperglycemic properties with a very safe adverse effect profile (weight neutral without 
causing hypoglycemia). 
The DPP-4 inhibitors based on their structure can be divided into those that 
mimic the DPP-4 molecule (peptidomimetics, vildagliptin and saxagliptin) and those 
that do not (non-peptidomimetics, sitagliptin, alogliptin, linagliptin).  
They are competitive reversible inhibitors of the DPP-4 substrate acting extra-
cellularly. The molecules have varying affinities toward the DPP-4 substrate 5. 
A list of available gliptins are follows 
 Sitagliptin (Merck Sharp and Dohme Corp, approved as Januvia by US FDA in 
year 2006) 
 Vildagliptin (Novartis, approved as Galvus by EU in year 2007) 
 Saxagliptin (Bristol-Myers Squibb, approved as Onglyza by US FDA in 2010) 
 Linagliptin (Boerhinger Ingelheim, approved as Tradjenta by US FDA in year 
2011) 
 Alogliptin (developed by Takeda Pharmaceutical Company Limited, approved for 
use in  Japan) 
 Teneligliptin (approved and marketed product in Japan since 2012 and in Korea 
since 2014) 
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Figure 2: Mechanism action of gliptins7 
 
 
EFFICACY OF DPP-4 INHIBITORS AND RECOMMENDATION FOR USE 
1. As monotherapy 
DPP-4 inhibitors have demonstrated a modest and comparable glycated 
hemoglobin lowering effect. Current guidance from the American Diabetes Association 
recommends an HbA1c goal of <7% for the most patient and stringent goal of <6.5 if 
this can be attained without significant hypoglycemia and side effects.5 
2. As initial dual therapy with other anti-diabetic agents 
DPP-4 inhibitors along with other anti-diabetic agents, significantly improved 
glycated hemoglobin when compared with monotherapy arms. 
In patients with T2DM inadequately controlled with metformin, SUs, or 
thiazolidinedione monotherapy, the addition of DPP-4 inhibitor was associated with 
significant improvements in HbA1c outcomes, as compared to placebo control.5 
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3. In triple combinations 
DPP-4 inhibitors consistently provided additive glycemic benefits. As add-on 
to metformin and SU or a TZD, individual DPP-4 inhibitors have each been observed 
to significantly reduce HbA1c from baseline as compared to dual therapy; and 
significantly increase the proportion of patients achieving A1C <7%.5 
SAFETY AND TOLERABILITY OF DPP-4 INHIBITORS 
1. Low risk for hypoglycemia 
A low risk of hypoglycemia was consistently observed in studies in treatment-
native patient receiving DPP-4 inhibitor monotherapy during 18 to 13 week therapy. 
Hypoglycemia was also low with DPP-4 inhibitor therapy administrated in dual and 
triple combination with metformin, an SGLT2 or a TZA. 
2. Weight gain 
A neutral or mildly beneficial effect on weight was observed when DPP-4 
inhibitors was used in combination regimens including metformin or an SGLT2. 
EFFICACY AND SAFETY IN PATIENTS WITH RENAL INSUFFICIENCY 
In patients with T2DM and moderate-to-severe chronic kidney disease, DPP-4 
inhibitors effectively improved glycemic outcomes, with an A1c-lowering effect 
ranging from -0.8% at 52 weeks, with two respective DPP-4 inhibitors. For patients 
with mild renal impairment, no dose adjustment is needed for the currently available 
DPP-4 inhibitors.5 
EFFICACY AND SAFETY OF DPP-4 INHIBITORS IN ELDERLY PATIENTS 
1. Efficacy profile 
 Available data in older patients demonstrate that DPP-4 inhibitors 
administered alone or in combination with other antidiabetic medications, 
effectively improve glycemic outcome in this patient population. 
2. Safety profile 
 Studies including elderly population showed that the incidence of adverse 
events are generally similar between the DPP-4 inhibitor group and 
comparator groups, and no notable safety issues were observed. 
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 There was a low risk of hypoglycemia DPP-4 inhibitor treatment groups. 
 A neutral or mildly beneficial effect on weight was observed in DPP-4 
inhibitor treatment groups. 5 
TENELIGLIPTIN 
Teneligliptin belongs to third generation DPP-4 inhibitor and it is approved for 
type 2 diabetes mellitus patients. It is a novel chemo type prolylthiazolidine based DPP-
4 inhibitor, shows a unique chemical structure which is characterized by five 
consecutive rings (J-shaped), thereby potentially producing unique characteristics 
including its glucose lowering efficacy and half-time.  
It is administered with 20- 40 mg once daily. Since the metabolites of this drug 
are excreted through hepatic (approximately35%) and renal (about 65%) route, no dose 
adjustment is necessary in patients with renal impairment. The efficacy and safety 
profiles of teneligliptin are similar to those of other DPP-4 inhibitors.  It because of its 
long half-life (approximately 26 hr.), this drug is shown to stabilize the glucose 
fluctuations throughout the day. 
Teneligliptin is a third generation DPP-4 inhibitor approved for treatment of 
type II diabetes. It is currently available in Japan, South Korea, Argentina and India. 
Teneligliptin is under pre-registration in Indonesia & under Phase I trials in US & Phase 
II trials in Denmark, Germany, Hungary, Lithuania, Poland, Romania & UK.5 
 
Chemistry of teneligliptin 
Teneligliptin, {(2S, 4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl) piperazin-
1-yl] pyrrolidin-2-yl} (1, 3-thiazolidin-3-yl) methanone hemipentahydrobromide 
hydrate exhibits a unique structure that is characterized by five consecutive rings and 
is peptidomimetic.  
An X-ray co-crystal structure of teneligliptin with DPP-4 demonstrates that the 
key interaction occurs between the phenyl ring on the pyrazole and the S2 extensive 
subsite of DPP-4, which not only enhances the potency of the drug but also increases 
its selectivity.1 
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Figure 3: Chemical structure of Teneligliptin6 
 
Metabolism and excretion 
CYP3A4, a cytochrome P450 isozyme and flavin-containing monooxygenases 
(FMO1 and FMO3) play major roles in the metabolism of teneligliptin. In vitro, 
teneligliptin exhibits a weak inhibitory effect for CYP2D6, CYP3A4, and FMO; 
however, it demonstrates no inhibitory effect for CYP1A2, CYP2A6, CYP2B6, 
CYP2C8, CYP2C8/9, CYP2C19, and CYP2E1. In addition, teneligliptin does not 
induce the expression of CYP1A2 or CYP3A4. 
About 34.4% of teneligliptin is excreted unchanged via the kidney and the 
remaining 65.6% teneligliptin is metabolized and eliminated via renal and hepatic 
excretion; 216 hours after the administration of 14C-labeled teneligliptin (20 mg), the 
cumulative excretion percentages of radioactive teneligliptin in urine and feces were 
45.4% and 46.5%, respectively.5 
Dosage & Administration 
The recommended dosage of Teneligliptin is 20 mg once daily. Teneligliptin 
can be administered irrespective of food, preferably before breakfast. It is also advisable 
to up titrate the dosage to 40 mg once daily in patients who do not achieve adequate 
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glycemic control as required. No dosage adjustment is required in patients with 
mild/moderate/severe renal impairment & mild/moderate hepatic impairment. 
No dosage adjustment is required in elderly patients. Efficacy & safety of Teneligliptin 
is not studied in children. Teneligliptin should be used with caution in patients with 
severe hepatic impairment &those with heart failure (NYHA Class III - IV), because of 
a lack of clinical experience in these populations.5 
Pharmacodynamic Advantage of Teneligliptin5 
 Unique Structural Advantage 
 Sustained DPP-4 Inhibition & High GLP-1 Concentration 
 Insulin/Glucagon Modulator 
 24 Hours Glucose Control 
 β-Cell Preservation 
 Reduction in Short-Term Glycemic Fluctuations 
Pharmacokinetic Advantage of Teneligliptin 
Teneligliptin is rapidly absorbed in healthy volunteers after a single 
radiolabeled 20 mg dose, with maximum plasma concentrations attained in 1.33 hr. The 
drug is 78% - 80% bound to plasma proteins. In humans, Teneligliptin is primarily 
metabolized by cytochrome P450 (CYP) 3A4 & flavin monooxygenases (FMO) 1 and 
3 to several metabolites of unknown biological activity. 
Pleiotropic Benefits of Teneligliptin 
 Improvement in Endothelial Function 
 Improvement in Lipid Profile 
 Natriuretic & Diuretic Effects of Teneligliptin 
 Weight Neutral 
 
SITAGLIPTIN 
This is the first gliptin to be US FDA approved. The recommended dose is 100 
mg once a day. Its absorption is unaffected by food. For patients with moderate renal 
impairment (creatinine clearance 30 to 50 mL/min) the recommended dose is 50 
mg/day and for severe renal impairment (creatinine clearance is <30 mL/min) the 
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recommended dose is 25 mg/day. In a meta-analysis it was shown to be more effective 
at reducing fasting blood sugar compared to vildagliptin, but overall efficacy was 
similar. 
Figure 4: Chemical structure of Sitagliptin 
 
The Asian study (China India Korea study) suggested that sitagliptin was more 
effective in the Indian population with greater HbA1c reductions of approximately 
1.3% compared to placebo.6 
VILDAGLIPTIN 
This is the second gliptin to be approved for commercial use although still not 
US FDA approved. The recommended dose is 50 mg twice a day. Its absorption is 
unaffected by food. It is extensively metabolized by the liver and has >90% 
bioavailability following a single oral dose. 
Figure 5: Chemical structure of Vildagliptin 
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No dosage adjustment is required for liver disease although a greater amount of 
inactive metabolites (30% greater) are retained in patients with severe liver disease 
(Childs grade C). In patients with renal impairment no dose adjustment is required for 
mild renal insufficiency however for moderate renal insufficiency half the 
recommended dose of 50 mg is suggested.7 
CURRENT POSITION OF GLIPTINS IN DIABETES MANAGEMENT 
GUIDELINES 
The American Diabetes Association (ADA), American Association of Clinical 
Endocrinologists (AACE), European Society, and NICE (UK) guidelines suggest that 
gliptins should be considered over other anti-diabetic therapies especially if the patient 
is experiencing an increased incidence of hypoglycemia and/or weight gain.  
It is clear that even major guidelines appreciate their usefulness with the only 
apprehension being that they have not withstood the test of time and therefore classified 
under less well-validated therapies. As data emerges suggesting sustained anit-
hyperglycenic benefits they should replace current practices that include popular use of 
SU +/– insulin as second and third line agents to metformin.8 
Current indications for use of gliptins are: 
1. First line in T2DM with HbA1c <7% 
2. Second line as add-on therapy in T2DM patients already on 1 out of the 
following {metfromin, SU, TZD, alfa-glucosidase inhibitor, miglitinide})for 
uncontrolled T2DM with HbA1c >7% 
3. Third line as add-on therapy in T2DM patients already on combination therapy 
(2 out of the following {metfromin, SU, TZD, alfa-glucosidase inhibitor, 
miglitinide) 
Contraindications or indication for stopping gliptin therapy includes previous 
or current adverse reaction to gliptins (hypersensitivity) or failure to achieve an HbA1c 
reduction of greater than 0.5% over a 6 month period. 
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Gliptins have revolutionized the concept of diabetes management and have 
provided a breath of fresh air to healthcare professionals dealing with diabetes. They 
provide an effective and safe alternative to the management of diabetes. Shown to 
reduced HbA1c from 0.5 to up to 2% effectively and safely (weight neutral without any 
if at all hypoglycemia) this new class of drugs is here to stay. 
 Even major diabetes management guidelines have acknowledged them for their 
safe adverse effect profile and urge healthcare professionals to use gliptins should they 
be struggling with regards weight or hypoglycemias with their patients. Recently, 
plagued with issues such as pancreatitis and cancer, these drugs need to stand the test 
of time and should they emerge victorious they will represent the only class of drugs 
that help improve beta-cell health, addressing the original triumvirate pathogenetic 
theory proposed for T2DM.8 
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2. REVIEW OF LITERATURE 
1. Manish Maladkar, 5 et al., conducted a study on 194 patients with type II 
diabetes mellitus, were treated for 120 days with teneligliptin (20 mg/day) alone 
teneligliptin add on Glimepiride. Result shows that teneligliptin offers unique 
pharmacokinetic advantage with long half-life of 26.9 hours allowing convenient 
once daily administration irrespective of food. It has unique dual mode of 
elimination via renal & hepatic, and hence can be administered safely in patients 
with renal impairment.  
2. Wakaba Tsuchimoch, 9 et al., conducted study on ten patients with type 2 
diabetes mellitus, were treated for 3 days with teneligliptin (20 mg/day). 
Postprandial profiles for glucose, insulin, glucagon, active glucagon-like 
peptide-1, active glucose-dependent insulinotropic polypeptide (GIP), and 24 h 
glycemic fluctuations were measured via continuous glucose monitoring for 4 
days. The result show that teneligliptin improved 24hours blood glucose levels 
by increasing active incretin levels and early-phase insulin secretion, reducing 
the postprandial insulin requirement, and reducing glucagon secretion. Even 
short-term teneligliptin treatment may offer benefits for patients with T2DM. 
3. Abhijeet Jain, 10 et al., The study was conducted as patients were randomly 
allotted into two groups. 50 patients were started with teneligliptin 20 mg/day 
along with metformin 1000 mg/day.Both group subjects had high FBS, PPBS 
and HbA1c at the start of study. After 24 weeks of treatment with teneligliptin 
and metformin, subjects had significant decrease in FBS, PPBS and HbA1c.This 
study showed that teneligliptin can be an effective alternative to other drugs for 
add on therapy to the patients who are inadequately controlled with metformin 
alone. 
4. Merlin C. Thomas, 11   et al., conducted study on 12-week, randomized, placebo-
controlled trials on DPP-4 inhibitors in C50 patients with T2DM and RI. 
Outcomes assessed by change in HbA1c, overall safety, and incidence of 
hypoglycemic events (HEs).The result which shows that HbA1c reductions were 
similar at weeks 12 and 52. In the 12-week, placebo-controlled phase, sitagliptin 
and vildagliptin reduced HbA1c levels by 0.6–0.7.  So that DPP-4 inhibitors have 
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the potential to improve glycemic control in patients with RI without increasing 
the risk of overall AEs. 
5. Fuyuhiko Marubayashi, 12 et al., conducted post-hoc pooled analysis used data 
from two Phase III clinical studies involving 702 Japanese patients. Evaluated 
teneligliptin as monotherapy and combined with a sulfonylurea, glinide, 
biguanide, or a-glucosidase inhibitor. Safety measures included adverse events 
(AEs), adverse reactions and hypoglycemia. .Which shows that Hypoglycemia 
was more frequent in the sulfonylurea combination therapy group than in other 
groups. Teneligliptin administered once daily as monotherapy or combination 
therapy resulted in a decrease in HbA1c, which was maintained for 52 weeks. 
6. Hamamoto.Y, 13 et al., study conducted a  12- or 16-week, placebo-controlled 
phase 2 and 3 trials, oral teneligliptin 20 or 40 mg once daily, as monotherapy or 
in combination with metformin, glimepiride or pioglitazone improved glycaemic 
control, including in patients with end-stage renal disease, and was generally 
well tolerated. This result shows that teneligliptin is a useful treatment option for 
adults with T2DM who have not responded adequately to diet and exercise 
regimens, or the addition of antidiabetic drugs. 
7. Takashi Kadowaki, 14 et al., conducted a teneligliptin as monotherapy and 
combined with a sulfonylurea, glinide, biguanide, or a-glucosidase inhibitor. 
Safety measures included adverse events (AEs), adverse reactions and 
hypoglycemia. The main efficacy measure was the change in glycated 
hemoglobin (HbA1c) from baseline. And this pooled analysis provides evidence 
for the safety and efficacy of long-term use of teneligliptin as monotherapy or 
combination therapy in Japanese T2DM patients. 
8. Takehiro Hashikata, 15 et al., conducted a study on 29 patients who had 
insufficiently controlled diabetes and consented to the study protocol were 
enrolled. All participants were evaluated at baseline and at 3 months after the 
additional treatment with teneligliptin. The study shows that the Teneligliptin 
treatment was associated with improvements in LV function and endothelial 
functions, and an increase in serum adiponectin levels. These results support the 
cardio-protective effects of teneligliptin in T2DM patients and increase in serum 
adiponectin levels. 
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9. Rika Ito, 16 et al., an open-label, prospective clinical study was conducted. 
Thirteen patients (mean age 55.5 ± 3.9 years) with T2D underwent OGTT before 
and after teneligliptin 20 mg/day monotherapy. Plasma levels of glucose (PG), 
insulin, and C-peptide were measured at 0, 30, 60, 90, and 120 min after glucose 
loading in the OGTT. The result shows that twelve weeks of teneligliptin 
treatment improved IGI30min, AUC120min, and the SUIT index in Japanese 
patients with T2D. 
10. Enrique Z. Fismanet, 17 et al., the study conducted in 3 years of treatment, 
approximately 50 % of diabetic patients could achieve acceptable glucose levels 
with monotherapy. And monitored about the HbA1c, PPBS, FBS and also lipid 
profile .Study results shows that a definite relationship between gliptins 
treatment in hyperglycemia and improved cardiovascular outcomes remains 
uncertain and needs yet to be proven. 
11. Yuya Nakamura, 18 et al., the effects of dipeptidase-4 (DPP-4) inhibitors in 
diabetic hemodialysis (HD) patients, the findings have yet to be reviewed 
comprehensively. Eyesight failure caused by diabetic retinopathy and aging-
related dementia make multiple daily insulin injections difficult for HD patients. 
The result shows that treating HD patients with DPP-4 inhibitors does not result 
in an increased incidence of adverse events. Furthermore, DPP-4 inhibitors are 
strongly anticipated to be effective in HD patients with diabetes. 
12. Valentina Lukashevich, 19 et al., conducted a study compared the safety and 
efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe 
renal impairment (RI). This study was a parallel-arm, randomized, multicenter, 
double-blind, 24 week study. In each group glycemic parameters are meauserd.  
Results shows that compared with sitagliptin demonstrated similar efficacy and 
both drugs were well tolerated. 
13. Jun-ichiro Mera, 20 et al., conducted a study with Vildagliptin 50 mg once daily 
was administered for 2 years. Various glycemic parameters are measured.The 
study concluded that Vildagliptin is a promising therapeutic option for safe, 
effective glycemic control in type 2 diabetic patients with ESRD 
14. Hirotoshi Ohmura, 21 et al., conducted study on 3,247 subjects treated with 
sitagliptin were retrospectively recruited. Glucose parameters were collected at 
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baseline, and 1, 3 and 6 months after initiation of sitagliptin. And also check 
whether about the sitagliptin-induced reduction in HbA1c using linear mixed 
effect model. The result shows that reduced HbA1c level from 7.44±1.20% at 
baseline to 6.73±0.99% at 6 months. So the sitagliptin is effective for diabetic 
management and generally well tolerated in Japanese patients with type 2 
diabetes. 
15. Yun‑Zhao Tang, 22 et al., conducted a study on randomized study on oral 
hypoglycemic agents such that vildagliptin and sitagliptin used in 535 T2DM 
patients. Body mass index, HbA1c, FPG and PPG, insulin dose, and adverse 
events were evaluated during the study. The result shows that the baseline 
HbA1c was reduced by vildagliptin is 66.27 % and  52.73 % sitagliptin.so that 
the study concluded that DPP-4 inhibitors appear to be effective and safe as add-
on therapy for T2DM patients on dual combination of insulin and a traditional 
OHA. Vildagliptin was more effective in decreasing insulin requirement and 
achieving glycemic control when compared to the other two.  
16. Eiji Kutoh, 8 et al., newly diagnosed, drug naive Japanese subjects with type 2 
diabetes (T2DM) were assigned to 20 mg/day teneligliptin monotherapy (n = 
31). At 3 months, levels of glycemic and other parameters were compared with 
those at baseline. Result shows that Teneligliptin might be effectively and safely 
used as an initial therapy for newly diagnosed T2DM. Glycemic efficacy of 
teneligliptin is obtained through activating beta-cell function as well as 
decreasing insulin resistance. 
17. Atef Halabi, 23 et al., teneligliptin was compared in 3 groups of 8 subjects 
assigned according to their degree of hepatic impairment (mild, moderate, or 
matched healthy subjects). Hepatic impairment was associated with an increase 
in maximal plasma concentration and overall exposure to teneligliptin. Study 
shows that teneligliptin was well tolerated by subjects with hepatic impairment. 
These results may indicate that caution will be needed when administering 
teneligliptin to subjects with hepatic impairment. 
18. Seiichi Tanaka, 24 et al., conducted Twenty-six patients with type 2 diabetes 
were admitted for glycemic control. After admission, patients continued to be 
treated with optimal dietary therapy plus insulin therapy, with or without other 
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anti-diabetes drugs, until they achieved stable glycemic control. The result shows 
that Add-on treatment with teneligliptin led to significant improvements in 24-h 
mean glucose levels, the proportion of time in normo glycemia, mean amplitude 
of glycemic excursions, and total area under the curve within 2 h after each meal.  
19. Wakaba Tsuchimochi, 25 et al., conducted a Ten patients with T2DM were 
treated for 3 days with teneligliptin (20 mg/day). Postprandial profiles for 
glucose, insulin, glucagon, active glucagon-like peptide-1 (GLP-1), active 
glucose-dependent, fluctuations were measured via continuous glucose 
monitoring for 4 days. Once daily teneligliptin administration for 3 days 
significantly lowered postprandial and fasting glucose levels. The result shows 
that Teneligliptin improved 24 h blood glucose levels by increasing active 
incretin levels and early-phase insulin secretion, reducing the postprandial 
insulin requirement, and reducing glucagon secretion. Even short-term 
teneligliptin treatment may offer benefits for patients with T2DM.  
20. Brian Green, 26 et al., conducted 70 patients with type 2 diabetes were admitted 
for glycemic control. After admission, patients continued to be treated with 
optimal dietary therapy plus insulin therapy, with or without other antidiabetic 
drugs, until they achieved stable glycemic control .the result shows that Gliptins 
increase nutrient-stimulated insulin secretion in type 2 diabetes with low-risk of 
hypoglycemia and without weight gain. 
21. Line P. Malha, 27 et al., conducted a study randomized open-label clinical trial 
that recruited 69 patients with previously treated with a combination therapy of 
metformin and sulphonylurea. Patients in the control group were maintained on 
their usual metformin and sulphonylurea regimen with dose adjustment for the 
fasting period. Patients in the study group were given vildagliptin 50 mg twice 
daily. Result shows that calculated change in hemoglobin A1C from baseline to 
last visit was similar for both groups.  
22. Fatemeh Hayati, 28 et al., study conducted in 24-week, non-randomized, open-
labeled trial study, T2DM patients (n=93) who were on optimum dosage of 
metformin and sulphonylurea were additionally treated with 100 mg sitagliptin 
daily. The end point was assessed by investigating the changes in HbA1c and 
also FPG. Safety was assessed by recording of hypoglycemia, change in body 
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mass index, blood pressure, lipid profiles HDL, LDL, total cholesterol (Tc) and 
triglycerides, AST, ALT, ALP, urea, uric acid and creatinine level. And the result 
shows that mean HbA1c was reduced by 0.41%, and overall, 18.27% of patients 
achieved an HbA1c goal of <7%. After 6 months study concluded that Sitagliptin 
is effective and safe to be used in combination with metformin and sulphonylurea 
therapies. 
23. Chun-Jun Li, 29 et al., conducted study on randomized, open-label, parallel 
clinical trial, enrolled inadequately controlled [HbA1c] ≥7.5% to ≤10%) patients 
with type 2 diabetes, who were treated by dual combination oral hypoglycemic 
agents and patients had been randomized to add-on 5 mg saxagliptin group or 
100 mg sitagliptin once daily group, or 50 mg vildagliptin twice daily group for 
24 weeks. HbA1c, FBG and P2hBG, body weight, BMI, episodes of 
hypoglycemia and adverse events were evaluated. And the result shows that 
After 24 weeks, HbA1c, FBG, and P2hBG of each group were significantly 
decreased. 
24. Dongsheng Cheng, 30 et al., study conducted on randomized-controlled trials 
that assessed the efficacy and safety of DDP-4 inhibitors compared with placebo, 
no treatment, or active drugs were identified using PubMed, and EMBASE. The 
result which shows that DPP-4 inhibitors reduced HbA1c significantly and had 
no increased risk of hypoglycemia or weight gain. So that DPP-4 inhibitors are 
effective at lowering HbA1c in T2DM patients with moderate to severe renal 
impairment. DPP-4 inhibitors also have a potential advantage in lowering the 
risk of adverse events. 
25. Paul Craddy, 31 et al., study  conducted on Systematic review of randomized 
controlled trials, health economic evaluation studies, systematic reviews, and 
meta-analyses, followed by primary Bayesian Mixed treatment comparison 
meta-analyses (MTCs), and secondary frequents direct comparison a Meta-
analyses using a random effects model. And which shows that this systematic 
review and MTC showed similar efficacy and safety for DPP-4 inhibitors as 
treatment for type 2 diabetes, either as monotherapy or combination therapy. 
26. Yoshinobu Nabikaru, 32 et al., the absorption, metabolism and excretion of 
teneligliptin were investigated in healthy male subjects after a single oral dose 
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of 20  mg teneligliptin. This study indicates the involvement of renal excretion 
and multiple metabolic pathways in the elimination of teneligliptin from the 
human body. Teneligliptin is unlikely to cause conspicuous drug interactions or 
changes in its pharmacokinetics patients with renal or hepatic impairment, due 
to a balance in the elimination pathways. 
27. Kazuoki Kondo, 33 et al., In an initial 12-week, double-blind, placebo 
controlled, parallel-group study, patients (n = 204) were randomized to 
teneligliptin 20 mg or placebo once daily added to their stable pioglitazone 
therapy. This was followed by a 40-week, open-label period during which all 
patients received teneligliptin once daily. The end point HbA1c from baseline to 
week 12. Patients in the teneligliptin group showed significantly greater 
reductions in HbA1c compared with the placebo group at week. The change in 
fasting plasma glucose from baseline to week 12 was greater in the teneligliptin 
group than in the placebo group (P < 0.001). 
28. Miyako Kishimoto, 34 et al., assess blood glucose control over 24 hours and the 
safety of teneligliptin at 10 and 20 mg doses, a randomized, double-blind, 
placebo-controlled, parallel-group study was conducted at four locations in 
Japan. Among the 99 patients who participated, 32 were treated with a placebo, 
34 were treated with teneligliptin at a dose of 10 mg, and 33 were treated with 
teneligliptin at a dose of 20 mg before breakfast for 4 weeks. These results 
indicate that the once-daily administration of teneligliptin before breakfast 
improved blood glucose control, even at dinnertime. 
29.  Sandhu-Minhas, 35 et al., study conducted as Retrospective population based 
cohort study. The cohort included 72 738 new users of oral antidiabetic drugs 
(8032 (11%) used sitagliptin; 7293 (91%) were taking it in combination with 
other agents) followed for a total of 182 409 patient years. Based on this study 
the result shows that Sitagliptin use was not associated with an excess risk of all 
cause hospital admission or death compared with other glucose lowering agents 
among newly treated patients with type 2 diabetes.  
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30. Masaya Sakamoto, 36 et al., conducted a study on  Twenty patients with type 2 
diabetes mellitus were randomly allocated to groups who received vildagliptin 
then sitagliptin, or vice versa. Patients were hospitalized at 1 month after starting 
each drug, and CGM was used to determine that 24-hour blood glucose level, 
fasting blood glucose level, highest postprandial blood glucose level and time, 
increase in blood glucose level after each meal, were measured. The study which 
shows that showed that mean 24-h blood glucose, highest blood glucose level 
after supper, and hyperglycemia after breakfast were significantly lower in 
patients with type 2 diabetes mellitus taking vildagliptin than those taking 
sitagliptin.  
31. Hyun Jeong Jeon, Tae Keun Oh, 37 conducted in a randomized, open-label, 
comparative study, and 106 patients with type 2 diabetes were enrolled. And 
HbA1c FPG, 2h-PPG reduction from baseline are monitored. Result shows that 
the comparable HbA1c reduction was observed with a mean±standard deviation 
change from baseline to the 32-week endpoint of -0.94±1.15% in the vildagliptin 
group and -1.00±1.32% in the glimepiride group. So that the gliptins are much 
better than the other oral hypoglycemic agents. 
32. Chahal. H, 38 et al., conducted 50 patients with type 2 diabetes were admitted 
for glycemic control under gliptins .the result shows that gliptins cause a modest 
reduction in glycated hemoglobin when used as monotherapy or combination 
therapy, of around 0.7–1%. They appear to be more potent when baseline 
glycated hemoglobin is higher. They appear to be well-tolerated, and are taken 
orally once daily. So these are useful in treating obese patients with type 2 
diabetes, in combination with metformin, or a glitazone, or both. 
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3. AIM AND OBJECTIVES 
AIM 
To determine the therapeutic efficacy and safety of Teneligliptin when 
compared with other standard gliptin molecules such as sitagliptin and vildagliptin. 
 
OBJECTIVES 
 Whether this drug used as primary, secondary or add on therapy as third 
molecule. 
 To find out whether it could be used as a monotherapy in special patients 
with metformin side effect. 
 Find out the usefulness of the teneligliptin and since it is low cost therapy to 
be recommended more than the other standard gliptins since it may quite 
useful in developing country like India. 
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4. METHODOLOGY 
STUDY SITE: 
This study was performed in the Department of General medicine 
(Diabetology), Kovai Medical Center and Hospital (KMCH) at Coimbatore, Tamil 
Nadu India. The proposed protocol for the study was presented and approved by the 
Hospital Ethical Committee (Annexure 1). 
STUDY DURATION: 
 The study period was from 25th February 2017 – 30th July 2017 (6 months). 
SOURCE OF DATA: 
Patient medical record - Patient medical record is observed and the required data 
such as age, op number, height, weight, FBS, PPBS, HbA1c, Serum creatinine, and 
SGPT was recorded. Other data such as educational status, material status, social habits, 
family history, employment status, duration of diabetes mellitus and adverse drug 
reactions were collected by directly interviewing the patient.  
STUDY DESIGN: 
The study is a hospital based prospective and retrospective observational study 
in which all the patients presented with type II diabetes mellitus to the General medicine 
department were considered. The study included describing data collected in terms of 
their level of measurement and summarizing them in forms of tables, graphs, and 
numerical values. Mainly the Paired Students‘t’ test and One-way ANOVA test was 
used to finalize the result. 
STUDY POPULATION: 
A total 155 patients who came to the General medicine department with type II 
diabetes mellitus were included in the study. 
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STUDY CRITERIA: 
Inclusion criteria: 
 Patients with type II diabetes with an HbA1C level ≥ 6.5%. 
  FBS level ≥ 126 mg/dl. 
  PPBS level ≥ 200 mg/dl. 
Exclusion criteria: 
 Patients with Type 1 diabetes. 
 Patients with Gestational diabetes.  
 Patients having more than 10% HbA1C  
METHODS OF DATA COLLECTION: 
 Patient case notes. 
 Medication/ treatment chart.  
 Laboratory data report & other relevant source.  
 Communication with the patients. 
STUDY PROTOCOL: 
Procedure: 
The study was carried out after an approval from the ethical committee of the 
hospital on 25th February 2016. According to the inclusion criteria the patient who had 
type II diabetes were included in the study.155 patients were studied by the time period 
of 6 months. Patients were divided in to three groups namely, Group-A teneligliptin (55 
patients), Group-B sitagliptin (50 patients) and Group-C vildagliptin (50 patients).  
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Figure 6: Patient Recruitment and Randomization 
 
Group-A was further divided in to 3 subgroups, 5 patients were on teneligliptin 
20mg as monotherapy, 25 patients on Teneligliptin add on Metformin as dual therapy. 
And 25 patients were on Teneligliptin add on Metformin plus Sulfonylurea as 
combination therapy. 
Group–B was further divided into two sub groups, containing each 25 patients 
Sitagliptin add on metformin as dual therapy, and Sitagliptin add on metformin plus 
sulfonylurea as combination therapy.  Group-C was also divided into two sub groups 
containing each 25 patients vildagliptin add on metformin as a dual therapy, and 
vildagliptin add on metformin plus sulfonylurea as combination therapy.  
The patients were followed monthly during the study registration period. At the 
time of entry, complete medical history, and laboratory evaluation were obtained. 
Patient demographics were also considered and recorded. The following procedures are 
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were performed before and after 3 months of teneligliptin, vildagliptin, sitagliptin 
treatment. HbA1C, FBS, PPBS, Serum Creatinine, SGPT were measured. These 
essential data were collected using data collection form. After 3 months treatment, these 
patients interviewed again to assess if there any adverse drug reactions.  
Literature Review: An extensive literature survey was done on safety, efficacy of 
gliptin molecule in type II diabetes mellitus patients. The literature supporting the study 
was gathered from various journal like Diabetes technology and therapeutics, 
International Journal of Pharma and Bio sciences, Scholar Journal of Applied Medical 
Sciences (SJAMS), International Journal of Research in Medical Sciences, Informa 
Health care, Journal of Diabetes Mellitus, Journal of Diabetes Ther,  Endocrine Journal 
and Advanced Publication, International Journal of Medical Sciences and Public 
Health, Journal Of Diabetes Research and Clinical Metabolism, Indian Journal of 
Endocrinology and Metabolism, Diabetes and Metabolism Journal. 
STATISTICAL ANALYSIS: 
Statistical analysis was performed using the IBM SPSS (statistical package for 
the social services) software version 20. The baseline characteristics were studied by 
percentage. Difference between the before and after treatment were examined for 
statistical significance using the student′s Paired t-test. ANOVA were performed to 
determine overall difference between before and after treatment groups. The result were 
presented as mean ± SD or %. In all cases p-value ≤ 0.005 was considered as statistically 
significant.   
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5. TABLES AND FIGURES 
 
Table 1: Distribution of overall study population based on gender (n=155) 
 
 
Figure 7: Plot of overall study population based on gender (n=155) 
 
 
 
 
 
 
MALE
59%
FEMALE
41%
Gender Frequency Percentage (%) 
Male 92 59 
Female 63 41 
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Table 2: Distribution of study population based on gender (n=150) 
 
 
Figure 8: Plot of study population based on gender (n=150) 
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Teneligliptin (n=50) Sitagliptin (n=50) Vildagliptin(n=50) 
Frequency 
Percentage 
(%) Frequency 
Percentage 
(%) Frequency 
Percentage 
(%) 
Male 31 21 29 19 29 19 
Female 19 13 21 14 21 14 
 Tables and Figures 
 
Department of Pharmacy Practice  28 
 
 
 
 
Table 3: Distribution of overall study population based on age (n=155) 
Age Frequency Percentage (%) 
30-40 20 13 
41-50 35 23 
51-60 67 43 
61-70 21 13 
71-80 12 8 
 
Figure 9: Plot of overall study population based on age (n=155) 
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Table 4: Distribution of patients based on Age Group (n=150) 
 
Figure 10: Plot of patients based on Age Group (n=150) 
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30-40 7 5 7 5 6 4 
41-50 12 8 11 8 11 8 
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61-70 6 4 7 4 7 5 
71-80 3 2 5 3 4 3 
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Table 5: Distribution of overall study population based on family-history (n=155) 
Family-history Frequency Percentage (%) 
Yes 69 45 
No 86 55 
 
 
Figure 11: Plot of overall study population based on family-history (n=155) 
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Table 6: Distribution of patients based on Family History (n=150) 
 
 
Figure 12: Plot of patients based on Family History (n=150) 
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Table 7: Distribution of overall study population based on duration  
of diabetes mellitus  (n=155) 
 
 
 
Figure 13: Plot of overall study population based on duration of diabetes mellitus 
(n=155) 
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Table 8: Distribution of patients based on Duration of Diabetes (n=150) 
 
 
Figure 14: Plot of patients based on Duration of Diabetes (n=150) 
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Table 9: Distribution of FBS (Dual therapy) levels in the study population (n=75) 
FBS 
Before Treatment After Treatment 
Mean ± SD Mean ± SD 
Teneligliptin + Metformin 168.92±24.55 123.62±10.12 
Sitagliptin + Metformin 168.68±24.13 123.64±10.45 
Vildagliptin + Metformin 168.16±23.91 142.89±21.16 
  
 
Figure 15: Plot FBS (Dual therapy) levels in the study population (n=75) 
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Table 10: Distribution of PPBS (Dual therapy) levels in the study  
population (n=75) 
 
 
 
Figure 16: Plot of PPBS (Dual therapy) levels in the study population (n=75) 
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PPBS 
Before Treatment After Treatment 
Mean ± SD Mean ± SD 
Teneligliptin + Metformin 274.56±37.62 165.10±35.15 
Sitagliptin + Metformin 273.32±39.12 165.11±36.12 
Vildagliptin + Metformin 275.88±36.27 190.44±44.29 
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Table 11: Distribution of HbA1C (Dual therapy) levels in the study  
population (n=75) 
 
 
Figure 17: Plot of HbA1C (Dual therapy) levels in the study population (n=75)  
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HbA1C 
Before treatment After treatment 
Mean ± SD Mean ± SD 
Teneligliptin + Metformin 8.77±0.90 7.1±0.51 
Sitagliptin + Metformin 8.81±0.91 7.1±0.56 
Vildagliptin + Metformin 8.73±0.91 7.9±0.75 
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Table 12: Distribution of Serum Creatinine (Dual therapy) levels in the study 
population (n=75) 
Serum Creatinine 
Before Treatment After Treatment 
Mean ± SD Mean ± SD 
Teneligliptin + Metformin 0.83±0.33 0.83±0.33 
Sitagliptin + Metformin 0.79±0.28 0.79±0.28 
Vildagliptin + Metformin 0.78±0.25 0.78±0.25 
 
 
Figure 18: Plot of Serum Creatinine (Dual therapy) levels in the study  
population (n=75) 
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Table 13: Distribution of SGPT (Dual therapy) levels in the study  
population (n=75) 
SGPT 
Before Treatment After Treatment 
Mean ± SD Mean ± SD 
Teneligliptin + Metformin 33.84±3.72 33.91±3.50 
Sitagliptin + Metformin 33.54±3.71 34.01±4.56 
Vildagliptin + Metformin 33.91±3.83 39.96±5.61 
 
 
Figure 19: Plot of SGPT (Dual therapy) levels in the study population (n=75) 
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Table 14: Distribution of FBS (Combination therapy) levels in the study 
population (n=75) 
FBS 
Before Treatment After Treatment 
Mean ± SD Mean ± SD 
Teneligliptin + Metformin + Glimepiride 193.8±34.30 121.5±22.69 
Sitagliptin + Metformin + Glimepiride 195.3±34.05 121.4±19.96 
Vildagliptin + Metformin + Glimepiride 193.4±28.66 132.9±25.07 
 
 
Figure 20: Plot of FBS (Combination therapy) levels in the study  
population (n=75) 
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Table 15: Distribution of PPBS (Combination therapy) levels in the study 
population (n=75) 
 
 
Figure 21: Plot of PPBS (Combination therapy) levels in the study  
population (n=75) 
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PPBS 
Before Treatment After Treatment 
Mean ± SD Mean ± SD 
Teneligliptin + Metformin + Glimepiride 294.7±43.80 183.44±19.84 
Sitagliptin + Metformin + Glimepiride 294.9±44.12 183.9±20.65 
Vildagliptin + Metformin + Glimepiride 294.5±41.89 199.4±23.25 
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Table 16: Distribution HbA1C of (Combination therapy) levels in the study 
population (n=75) 
HbA1C 
Before Treatment After Treatment 
Mean ± SD Mean ± SD 
Teneligliptin + Metformin + Glimepiride 0.93±0.94 7.49±0.48 
Sitagliptin + Metformin + Glimepiride 9.47±0.91 7.51±0.54 
Vildagliptin + Metformin + Glimepiride 9.48±0.93 8.60±0.79 
 
Figure 22: Plot of HbA1C (Combination therapy) levels in the study  
population (n=75) 
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Table 17: Distribution of SrCr (Combination therapy) levels in the study 
population (n=75) 
Serum Creatinine 
Before Treatment After Treatment 
Mean ± SD Mean ± SD 
Teneligliptin + Metformin + Glimepiride 0.83±0.34 0.83±0.34 
Sitagliptin + Metformin + Glimepiride 0.79±0.24 0.79±0.24 
Vildagliptin + Metformin + Glimepiride 0.82±0.31 0.82±0.31 
 
 
Figure 23: Plot of SrCr (Combination therapy) levels in the study  
population (n=75) 
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Table 18: Distribution of SGPT (Combination therapy) levels in the study 
population (n=75) 
 
 
Figure 24: Plot of SGPT (Combination therapy) levels in the study  
population (n=75) 
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SGPT 
Before Treatment After Treatment 
Mean ± SD Mean ± SD 
Teneligliptin + Metformin + Glimepiride 28.68±5.59 28.76±6.12 
Sitagliptin + Metformin + Glimepiride 30.64±6.31 31.44±6.92 
Vildagliptin + Metformin + Glimepiride 28.36±5.32 30.19±5.61 
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Table 19: Distribution of mean reduction in Glycemic parameters (Teneligliptin) 
in the study population (n=75) 
 
 
Figure 25: Plot of mean reduction in Glycemic parameters (Teneligliptin) in the 
study population (n=75) 
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Category 
Mean 
reduction 
in HbA1C 
Mean 
reduction 
in FBS 
Mean 
reduction 
in PPG 
Teneligliptin 0.92 41.33 65.83 
Teneligliptin +Metformin 1.68 48.53 72.91 
Teneligliptin + Metformin + Glimepiride 1.97 55.68 88.53 
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Table 20: Distribution of ADRs (Teneligliptin) in the study population (n=50) 
 
Figure 26: Plot of ADRs (Teneligliptin) in the study population (n=50) 
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Table 21: Distribution of ADRs (Sitagliptin) in the study population (n=50) 
 
 
Figure 27: Plot of ADRs (Sitagliptin) in the study population (n=50) 
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GI irritation 6 12 
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Table 22: Distribution of ADRs (Vildagliptin) in the study population (n=50) 
 
 
Figure 28: Plot of ADRs (Vildagliptin) in the study population (n=50) 
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GI irritation 4 8 
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Table 23: Distribution of cost effectiveness in Monotherapy 
 
 
 
Table 24: Distribution of Cost effectiveness in Combination therapy 
 
 
 
 
 
 
Group Drug Price of a tablet 
Price for 3 
months 
Difference 
Monotherapy 
Teneligliptin 7.69 692.1  
Sitagliptin 38.4 1080 30.71 
Vildagliptin 25.7 2313 18.01 
Group Drug 
Price of a 
tablet 
Price for 3 
months 
Difference 
Combination 
therapy 
Teneligliptin + Metformin 12 1080  
Sitagliptin + Metformin 23.2 2088 11.2 
Vildagliptin + Metformin 26.52 2386 14.52 
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Table 25: Student paired t-test for Dual therapy (n=75) 
* ≤ 0.005 is considered as statistically significant. 
 
Parameter Dual therapy 
Before 
Treatment 
After 
Treatment 
t-value p- value 
Mean ± SD Mean ± SD   
FBS 
Teneligliptin+ Metformin 168.92±24.55 123.62±10.12 10.04 ≤0.000*** 
Sitagliptin + Metformin 168.68±24.13 123.64±10.45 5.807 ≤0.000*** 
Vildagliptin + Metformin 168.16±23.91 142.89±21.16 12.03 ≤0.000*** 
PPBS 
Teneligliptin +Metformin 274.56±37.62 164.16±35.15 16.47 ≤0.000*** 
Sitagliptin+ Metformin 273.32±39.12 165.11±36.12 21.25 ≤0.000*** 
Vildagliptin+ Metformin 275.88±36.27 190.44±44.29 10.41 ≤0.000*** 
HbA1C 
Teneligliptin+ Metformin 8.77±0.90 7.1±0.51 9.49 ≤0.000*** 
Sitagliptin+ Metformin 8.81±0.91 7.1±0.56 11.56 ≤0.000*** 
Vildagliptin+ Metformin 8.73±0.91 7.9±0.75 18.2 ≤0.000*** 
SRCR 
Teneligliptin+ Metformin 0.83±0.33 0.83±0.33 1.732 0.104 
Sitagliptin+ Metformin 0.79±0.28 0.79±0.28 1.693 0.103 
Vildagliptin+ Metformin 0.78±0.25 0.78±0.25 1.693 0.103 
SGPT 
Teneligliptin+ Metformin 33.84±3.72 33.91±3.50 -1.875 0.073 
Sitagliptin+ Metformin 33.54±3.71 34.01±4.56 -1.82 0.081 
Vildagliptin+ Metformin 33.91±3.83 39.96±5.61 -2.48 0.21 
 Tables and Figures 
 
Department of Pharmacy Practice  50 
 
 
 
Table 26: Student paired t-test for Combination therapy (n=75) 
 
* ≤ 0.005 is considered as statistically significant. 
 
 
 
Parameter Combination therapy 
Before 
Treatment 
After 
Treatment 
t-value p-value 
Mean ± SD Mean ± SD 
FBS 
TENE+MET+GLI 193.8±34.30 121.5±22.69 10.25 ≤0.000*** 
SITA+MET+GLI 195.3±34.05 121.4±19.96 11.44 ≤0.000*** 
VILA+MET+ GLI 193.4±28.66 132.9±25.07 9.27 ≤0.000*** 
PPBS 
TENE+MET+ GLI 294.7±43.80 183.44±19.84 13.01 ≤0.000*** 
SITA+MET+ GLI 294.9±44.12 183.9±20.65 15.37 ≤0.000*** 
VILA+MET+ GLI 294.5±41.89 199.4±23.25 14.89 ≤0.000*** 
HbA1C 
TENE+MET+ GLI 0.93±0.94 7.49±0.48 11.29 ≤0.000*** 
SITA+MET+ GLI 9.47±0.91 7.51±0.54 10.64 ≤0.000*** 
VILA+MET+ GLI 9.48±0.93 8.60±0.79 20.7 ≤0.000*** 
SRCR 
TENE+MET+ GLI 0.83±0.34 0.83±0.34 0 1 
SITA+MET+ GLI 0.79±0.24 0.79±0.24 -450 0.657 
VILA+MET+ GLI 0.82±0.31 0.82±0.31 -157 0.877 
SGPT 
TENE+MET+ GLI 28.68±5.59 28.76±6.12 -0.097 0.927 
SITA+MET+ GLI 30.64±6.31 31.44±6.92 -0.525 0.605 
VILA+MET+ GLI 28.36±5.32 30.19±5.61 -5.07 0.621 
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Table 27:One-Way ANOVA test for Dual therapy (n=75) 
 
* ≤ 0.005 is considered as statistically significant. 
 
 
 
 
 
Parameter Dual therapy 
Before 
Treatment 
Before 
Treatment 
After 
Treatment 
After 
Treatment 
f p-value f p-value 
FBS 
Sitagliptin+ Metformin 1.619 0.179 0.215 1.86 
Vildagliptin+ Metformin 3.242 0.012 0.043 ≤0.000*** 
PPBS 
Sitagliptin+ Metformin 2.431 0.539 0.214 0.635 
Vildagliptin+ Metformin 2.865 0.008 2.415 ≤0.000*** 
HbA1c 
Sitagliptin+ Metformin 1.74 2.87 0.192 0.826 
Vildagliptin+ Metformin 2.184 0.12 2.905 ≤0.000*** 
SrCR 
Sitagliptin+ Metformin 1.823 0.151 0.811 0.575 
Vildagliptin+ Metformin 1.823 0.151 0.811 0.575 
SGPT 
Sitagliptin+ Metformin 0.923 0.541 0.701 0.701 
Vildagliptin+ Metformin _ _ 13.901 0.141 
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Table 28: One-Way ANOVA test for Combination therapy (n=75) 
 
* ≤ 0.005 is considered as statistically significant. 
 
 
 
Parameter 
Combination 
therapy 
Before 
Treatment 
Before 
Treatment 
After 
Treatment 
After 
Treatment 
f p-value f p-value 
FBS 
SITA+MET+GLI 1.434 0.26 0.373 0.693 
VIDA+MET+ GLI 1.941 0.167 14.351 ≤0.000*** 
PPBS 
SITA+MET+ GLI 1.873 0.155 1.488 0.248 
VIDA+MET+ GLI 0.113 0.976 9.375 ≤0.000*** 
HbA1c 
SITA+MET+ GLI 0.821 0.497 0.892 0.424 
VIDA+MET+ GLI 0.594 0.626 9.24 ≤0.000*** 
SrCr 
SITA+MET+ GLI 0.846 0.551 1.24 0.333 
VIDA+MET+ GLI 0.787 0.592 1.417 0.262 
SGPT 
SITA+MET+ GLI 0.885 0.594 1.528 0.25 
VIDA+MET+ GLI _ _ 3.366 0.03 
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 6. RESULTS AND ANALYSIS 
A total 155 patients with type II diabetes mellitus was included in this study. 
They were divided into three groups namely Group A-Teneligliptin, Group B- 
Sitagliptin and Group C-Vildagliptin. 
They were further divided into three sub-groups, teneligliptin 20 mg as 
monotherapy (5 patients), Teneligliptin and Metformin as dual therapy (25 patients) 
and Teneligliptin and Metformin with Glimepiride as combination therapy (25 
patients). 
Group B was divided into the two sub-groups, containing each 25 patients 
Sitagliptin with Metformin as dual therapy and Sitagliptin with Metformin plus 
Glimepiride as combination therapy. 
Group C was divided into the two sub-groups, containing each 25 patients 
Vildagliptin with Metformin as a dual therapy and Vildagliptin with Metformin plus 
Glimepiride as combination therapy. 
GENERAL BASE LINE CHARACTERISTICS OF STUDY POPULATION: 
The patients were categorized based on their gender. There were 92 males and 
62 females in overall study population, 31 males and 19 females in group A and 29 
males and 21 females in Group B and Group C.  The results shows the higher 
predominance in male for type II diabetes mellitus. (Table 1, 2 and Figure 7, 8) 
Study population was categorized in to 5 groups on the basis of age. Among the 
5 groups more number of patients were came under the category of 51-60 and less in 
71-80 category. This indicates that incidence of type II diabetes mellitus is higher in 
51-60 years and lower in 71-80 years.  (Table 3, 4 and Figure 9, 10) 
Among the study population, more number of patients (58%, 54% and54% in 
group A, B and C   respectively) were known to have no family history of type II 
diabetes mellitus. (Table 5, 6and Figure 11, 12) 
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  Study population was categorized into two groups on the basis of duration of 
the disease in years. More number of patients were came under category 0-5 years and 
less in 6-10 years. (Table 7, 8 and Figure 13, 14) 
GLYCEMIC CONTROL: 
The glycemic efficacy was assessed by analyzing the mean change in the value 
of Fasting Blood Sugar (FBS), Post Prandial Blood Sugar (PPBS), and Glycated 
hemoglobin (HbA1c) from the start of the therapy to the end of 3 months study period 
in each group. 
Clinical efficacy of teneligliptin 
At the end of 3 months of dual therapy mean HbA1c, FPG, and PPG were 
significantly (p value-≤0.0001) reduced by 7.1±0.5% 123.62±9.31mg/d L and 
164.16±35.15mg/d L respectively. (Table 9, 10, 11 and Figure 15, 16, 17) 
  At the end of 3 months combination therapy the following results were noted (p 
value-≤0.0001) reduction in HbA1c, FPG, PPG by 7.49±0.48% 121.5±22.69mg/d L 
and 183.44±19.84mg/d L respectively. (Table 14, 15, 16 and Figure 20, 21, 22) 
The mean reduction of HbA1c was found to be 0.92% in monotherapy, 1.68% 
in dual therapy and 1.79% in combinational therapy. (Table 19 and Figure 25) 
The mean reduction of FBS was found to be 41.33 mg/d L. in monotherapy, 
48.53 mg/d L in dual therapy and 55.68 mg/d L. in combinational therapy (Table 19 
and Figure 25) 
The mean reduction of PPBS was found to be 61.58mg/d L. in monotherapy, 
72.71mg/d L in dual therapy and 88.53 mg/d L. in combinational therapy. (Table 19 
and Figure25)  
Clinical efficacy of Sitagliptin: 
After the 3 months treatment with sitagliptin significant reduction of HbA1c, 
FPG, and PPG level were observed.  Mean HbA1c, FPG, and PPG of dual therapy was 
  
 
Results and Analysis 
 
Department of Pharmacy Practice  55 
 
 
 
significantly (p value-≤0.0001) reduced by 7.16±0.56% 123.64±20.24mg/d L and 
165.11±30.16mg/d L respectively. (Table 9, 10, 11 and Figure 15, 16, 17) 
Combination therapy shown significant (p value-≤0.0001) reduction in HbA1c, 
FPG, PPG by 7.51±0.54% 121.41±19.96mg/d L and 183.9±20.65mg/d L respectively. 
(Table 14, 15, 16 and Figure 20, 21, 22) 
Clinical efficacy of Vildagliptin: 
After the 3 months treatment, dual therapy mean HbA1c, FPG, and PPG were 
significantly (p value-≤0.0001) reduced by 7.9±0.75%, 142.89±21.10mg/d L and 
190.44±29.29mg/d L respectively. (Table 9, 10, 11 and Figure 15, 16, 17) 
Combination therapy shown significant (p value-≤0.0001) reduction in HbA1c, 
FPG, PPG by 8.60±0.48% 132.9±25.07mg/d L and 199.49±21.80mg/d L respectively. 
(Table 14, 15, 16 and Figure 20, 21, 22) 
COMPARITIVE ANALYSIS 
GROUP A ((TENELIGLIPTIN AND ITS COMBINATIONS) VERSUS GROUP C 
(VILDAGLIPTIN AND ITS COMBINATIONS)   
Effect on HbA1c 
Post 3 months of treatment for the two groups are shown below. The mean 
HbA1c of the dual therapy for group -A (teneligliptin with metformin) was 7.1±0.5% 
and group C (Vildagliptin with metformin) therapy 7.9±0.75 %.( Table 11 and 
Figure17) 
The mean HbA1c of combination therapy was found to be (teneligliptin with 
metformin plus glimepiride) 7.49±0.48%, which was significantly lower than the mean 
HbA1c in 8.60±0.48%   in group C (Vildagliptin with metformin plus glimepiride) 
therapy. (Table 16 and Figure 22) 
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It is clearly evident that Group -A (dual and combination therapy) patients had 
greater reduction in HbA1c level when compared to Group C (dual and combination 
therapy). 
Effect on FBS 
In group A the mean FBS of dual therapy (teneligliptin with metformin) 
was123.62±9.31mg/d L which was significantly lower than the mean FBS in 
142.89±21.10mg/d L in group C (Vildagliptin with metformin) therapy. (Table 9 and 
Figure 15) 
In group A the mean FBS of combination therapy (teneligliptin with metformin 
plus glimepiride) was 121.5±22.69mg/d L, which was significantly lower than the mean 
FBS in 132.9±25.07mg/d L in group C (Vildagliptin with metformin plus glimepiride) 
therapy. (Table 14 and Figure 20) 
It is shows Group A (dual and combination therapy) patient had greater 
reduction of FBS than compared to Group C (dual and combination therapy). 
Effect on PPBS 
In group A the mean PPBS of dual therapy (teneligliptin add on metformin) was 
164.16±35.15mg/d L which was significantly lower than the mean PPBS in 
190.44±29.29mg/d L mg/d L in group C (Vildagliptin add on metformin) therapy. 
(Table 10 and Figure 16) 
In group A the mean PPBS of combination therapy (teneligliptin add on 
metformin plus glimepiride) was 183.44±19.84mg/d L which was significantly lower 
than the mean PPBS in 199.49±21.80mg/d L in group C (Vildagliptin add on metformin 
plus glimepiride) therapy. (Table 15 and Figure 21) 
It is clearly evident that Group A (dual and combination therapy) patient had 
greater reduction of PPBS than compared to Group C (dual and combination therapy) 
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Effect on SrCr (Serum creatinine) and SGPT  
There was no significance difference was seen in SrCr level following 3 months 
of therapy with teneligliptin and its combinations when compared to  sitagliptin and its 
combinations and vildagliptin and its combinations. (Table 12, 17 and Figure 18, 23) 
SGPT level showed a slightly significant increase in all the three groups, but it 
was in normal range. (Table 13, 18 and Figure 13, 18) 
GROUP A (TENELIGLIPTIN AND ITS COMBINATIONS) VERSUS GROUP B 
(SITAGLIPTIN AND ITS COMBINATIONS) 
Effect on HbA1c 
A mean reduction in HbA1c of 7.1±0.5%, was seen with teneligliptin add on 
metformin therapy, while a same mean reduction in HbA1c of 7.1±0.5% was found 
with sitagliptin add on metformin therapy. Comparison both the groups demonstrated 
that there was no significant difference. (Table 11 and Figure17) 
Mean reduction in HbA1c of 7.49±0.48% was seen with teneligliptin with 
metformin plus sulfonyl urea therapy, while a slight increase of HbA1c of 7.51±0.54% 
was found with sitagliptin add on metformin plus glimepiride therapy. (Table 16 and 
Figure 22) 
Effect on FBS 
A mean reduction in FBS of 123.6±9.31mg/d L was seen with teneligliptin with 
metformin therapy, while a same mean reduction in FBS of 123.64±20.24mg/d L was 
found with sitagliptin with metformin therapy. Comparison both the groups 
demonstrated that there was no significant difference. (Table 9 and Figure 15)  
A mean reduction in FBS of 121.5±22.69mg/d L was seen with teneligliptin add 
on metformin plus glimepiride, while a slight decrease of FBS of 121.41±19.96mg/d L 
was found with sitagliptin add on metformin plus sulfonyl urea therapy. (Table 14 and 
Figure 20) 
  
 
Results and Analysis 
 
Department of Pharmacy Practice  58 
 
 
 
Effect on PPBS 
Mean reduction in PPBS of 164.1±35.15mg/d L, was seen with teneligliptin add 
on metformin therapy, while a same mean reduction in PPBS of 164.1±30.16mg/d L 
was found with sitagliptin add on metformin therapy. (Table 10 and Figure 16). On the 
comparison both the group demonstrated no difference statistically. 
A mean reduction in PPBS of 183.44±19.84mg/d L, was seen with teneligliptin 
add on metformin plus glimepiride, while a same mean reduction in PPBS of 
183.9±20.65mg/d L was found with sitagliptin add on metformin plus glimepiride 
therapy. On the comparison both the group demonstrated no difference statistically. 
(Table 15 and Figure 21) 
It shows that both the regimens on comparison reveled similar efficacy there by 
failing to prove the superiority over each other. 
Effect on SrCr and SGPT 
There was no significance difference between SrCr following 3 months of 
therapy with teneligliptin and its combinations when compared with sitagliptin and its 
combinations and vildagliptin and its combinations. (Table 12, 17 and Figure 18, 23) 
SGPT level showed a slightly significant increase in three groups, but which 
was still in normal range. (Table 13, 18 and Figure 19, 24) 
SAFETY ANALYSYS: 
Group-A 
Treatment with Teneligliptin and its combination was well tolerated over the 3 
months treatment period. . In monotherapy there were no ADR reported. 8 patients 
experienced ADRs .Mild hypoglycemia reported in (6%) the cases, was mostly reported 
ADR followed by GI irritation (8%) and less in headache (2%). (Table 20 and Figure 26) 
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Group-B 
There were no severe ADR is reported in Sitagliptin and its combination therapy 
.Mild GI irritation (12%) was occurred in the group. Other ADR including nausea (2%) 
and headache (2%) and diarrhea (4%) were happened among the group. No other 
frequently observed or serious ADR were observed in this study. And no hypoglycemia 
occurred in any of the patient taking vildagliptin and their combination. (Table 21 and 
Figure 27) 
Group-C 
The frequent ADR in the vildagliptin and their combination therapy were 
hypoglycemia (14%)   GI irritation (8%), headache (4%), dizziness (2%) and diarrhea 
(2%). No severe ADR were reported in the 3 groups. All the ADR reported during the 
study were mild. (Table 22 and Figure 28) 
 There were no incidence of renal and hepatic toxicity. There was no 
significance difference between groups in terms of reported ADR.  
COST EFFECTIVE ANALYSIS (CEA) 
The cost effectiveness of teneligliptin, sitagliptin, and vildagliptin monotherapy 
and their combination with metformin was studied. It shows that teneligliptin and its 
combination with metformin was found to be more cost effective. (Table 22 and 23) 
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7. DISCUSSION 
The study was designed to compare safety, efficacy and cost effectiveness of 
teneligliptin, sitagliptin and vildagliptin in type II diabetes mellitus patients. The study 
was started with 155 patients. Each gliptin were compared with metformin and add on 
therapy of metformin plus glimepiride. 
In this study the patients were categorized based on their gender. There were 31 
males and 19 females in teneligliptin group, 29 males and 21 females in sitagliptin 
group and vildagliptin group. The results shows the higher predominance in male for 
type II diabetes mellitus. This was similar to the previous studies conducted by Bennett 
et al., and Howteerakul et al., which showed higher prevalence of type II DM in men 
than women. 
In this study population was categorized in to 5 groups on the basis of age. 
Among the 5 groups more number of patients were came under the category of 51-60 
and less in 71-80 category. Type II DM is commonly seen in middle-aged individuals, 
especially after 50 years of age. The mean age in this study was 51-60 years, this fact 
is supported by the study conducted by Miyako Kishimoto et al., . 
Among the study population, more number of patients (58%, 54% and54% in 
group A, B and C respectively) were known to have no family history of type II diabetes 
mellitus. In this study, 40% patients had a positive family history indicating either one 
or both the parents had type II DM, which was at one stage or the other transferred from 
one generation to another. Also this was accordance with larger prospective study 
conducted by Bennett et al., . 
Study population was categorized into two groups on the basis of duration of 
the disease in years. More number of patients were came under category 0-5 years and 
less in 6-10 years. The average duration of DM in this study was found to be 0- 5 years, 
which was in line with a previous study conducted by Jeon et al., where the mean 
duration was 5.89 years. 
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The glycemic efficacy was assessed by analyzing the mean change in the value 
of Fasting Blood Sugar (FBS), Post Prandial Blood Sugar (PPBS), and Glycated 
hemoglobin (HbA1C) from the start of the therapy to the end of 3 months study period 
in each group. 
Teneligliptin has been demonstrated to improve glycemic control when 
monotherapy and added to glimepiride, metformin, in patients with type II diabetes. It 
is confirmed that the combination of Teneligliptin, metformin and glimepiride 
significantly improved glycemic control. However, in this study, the reduction in 
HbA1C with teneligliptin monotherapy was greater than those in teneligliptin 
metformin group and teneligliptin with metformin and glimepiride group. 
In this study shows at the end of 3 months of dual therapy mean HbA1C, FPB, 
and PPBS were significantly (p value-≤0.0001) reduced by 7.1±0.5% 123.62±9.31mg/d 
L and 164.16±35.15mg/d L respectively. At the end of 3 months combination therapy 
the following results were noted (p value ≤ 0.0001) reduction in HbA1C, FPG, PPG by 
7.49±0.48% 121.5±22.69mg/d L and 183.44±19.84mg/d L respectively. The result of 
this study perfectly complies with the former study conducted by,  Kim et al., studied 
in combination of teneligliptin with metformin in known type II diabetic Korean 
patients whose glycemic status were not under controlled with metformin monotherapy, 
this shows teneligliptin add on metformin plus glimepiride therapy shows the 
significant reduction of glycemic parameter. 
Another study conducted by in Ghosh et al., (TREAT-INDIA), there was 
statistically significant improvement in mean HbA1c, FPG, and PPG with teneligliptin 
therapy. Means changes in HbA1c, FPG, and PPG were 1.37%±1.15%, 51.29±35.41 
mg/dL, and 80.89±54.27 mg/dL, respectively. 
Subgroup analysis revealed that HbA1c (%) reduction with teneligliptin when 
used as monotherapy, add-on to metformin or add-on to metformin plus combination, 
was 0.98±0.53, 1.07±0.83, 1.46±1.33, respectively. 
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In this study the mean reduction of HbA1C was found to be 0.92% in 
monotherapy, 1.68% in dual therapy and 1.79% in combinational therapy and the mean 
reduction of FBS was found to be 41.33 mg/d L. in monotherapy, 48.53 mg/d L in dual 
therapy and 55.68 mg/d L. in combinational therapy. The mean reduction of PPBS was 
found to be 61.58mg/d L. in monotherapy72.71mg/d L in dual therapy and 88.53 mg/d 
L. in combinational therapy. The similar result were observed by, Kutoh et al., in a 
3‑month study of 31 drug naive Japanese T2DM patients, evaluated teneligliptin daily 
20 mg as a monotherapy. This study found a significant reduction in HbA1C and fasting 
blood glucose from the baseline. 
Scott et al., in his study suggested that Teneligliptin, a DPP-4 inhibitor was 
added to the armamentarium for use in patients with type II diabetes in India. In 
different clinical trials conducted in Japan, Korea, and India, it has been shown to be 
safe and effective in T2DM patients when used either as monotherapy and combination 
antidiabetic therapy. 
Recently an Indian study by Suryawanshi et al., reported the results of a 16-
week, multi centric, double-blind, placebo-controlled, Phase 3 studies of teneligliptin 
20 mg daily in drug naive T2DM patients. This study (N =237) reported a significant 
−0.55% glycated hemoglobin (HbA1C) reduction (placebo-subtracted) in teneligliptin 
arm (P = 0.0043) compared to control. While a significant reduction in 2 hrs 
postprandial glucose (PPG) (−25.8 mg/dl, P = 0.0070) versus placebo was observed, an 
insignificant reduction in fasting plasma glucose (FPG) was seen (−8.8 mg/dl, P =0.18) 
in teneligliptin 20 mg arm. Similarly, higher percentage of patient achieved the target 
HbA1c of <7% in teneligliptin arm (43.4% vs. 27.3%, P = 0.026) compared to the 
control and “overall” the drug was well tolerated. 
The similar results shows that Kadowaki et al., and  Kondo et al., conducted a 
double-blind placebo-controlled parallel-group study in 324 Japanese patients with type 
2 diabetes randomized to receive different doses of teneligliptin or placebo once daily 
before breakfast for 12 weeks. These results indicate that treatment with teneligliptin 
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for 12 weeks provided significant and clinically meaningful reduction in the levels of 
HbA1c and FPG across the dose range studied. 
Wakaba et al., study was to evaluate the effects of teneligliptin on 24 hour 
blood glucose control and gastrointestinal hormone responses to a meal tolerance test, 
and to investigate the glucose-lowering mechanisms of teneligliptin. Teneligliptin was 
given once a day for 3 days significantly lowered fasting and postprandial glucose 
levels. Significant elevations of fasting and postprandial active GLP-1 and postprandial 
active GIP levels were observed. 
In this study after the 3 months treatment with sitagliptin and its combination 
significant reduction of HbA1c, FPG, and PPG level were observed.  Mean HbA1c, 
FPG, and PPG of dual therapy was significantly (p value≤0.0001) reduced by 
7.16±0.56% 123.64±20.24mg/d L and 165.11±30.16mg/d L respectively. Combination 
therapy shown significant (p value≤ 0.0001) reduction in HbA1c, FPG, PPG by 
7.51±0.54% 121.41±19.96mg/d L and 183.9±20.65mg/d L respectively. 
This was in accordance with previous studies conducted by Goldstein et al., 
and Hermansen et al., where the effects of combination of sitagliptin + metformin with 
other oral hypoglycemics have been well documented. The improvement in HbA1c was 
highly significant in both the study groups (p < 0.001) at the end of 24 weeks. 
Previous studies by Hermansen et al., Raz et al., and Bennettet al., have 
proven the improvement in HbA1c by combination of metformin and sitagliptin and 
metformin and glimepiride. At the end of the study period, the intergroup comparison 
between groups I and II was done for FPG, PPG, and HbA1c. It was insignificant for 
FPG and HbA1C (p > 0.05) and significant for PPG (p < 0.05) indicating that the group 
where combination of sitagliptin and metformin was given had a better glycemic 
control in terms of PPG. 
Previous studies conducted by Reasner et al., Perez-Monteverde et al.,  and  
Wainstein et al., have proven that combination of sitagliptin and metformin produces 
significant improvement in glycemic parameters such as FPG, PPG, and HbA1c. 
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In this study after the 3 months treatment, dual therapy mean HbA1C, FPG, and 
PPG were significantly (p value ≤0.0001) reduced by 7.9±0.75%, 142.89±21.10mg/d L 
and 190.44±29.29mg/d L respectively. Combination therapy shown significant (p value 
≤ 0.0001) reduction in HbA1C, FPG, PPG by 8.60±0.48% 132.9±25.07mg/d L and 
199.49±21.80mg/d L respectively. 
Recent studies have shown that, Matthews et al., and Filozof et al., as add-on 
therapy in patients with inadequately controlled T2DM treated with vildagliptin, 
metformin dual therapy and vildagliptin metformin and Sulphonylurea as combination 
therapy. 
Masato Odawara et al., 12-week, randomized, double-blind study evaluated 
the efficacy and safety of vildagliptin 50 mg bid in Japanese patients with T2DM 
inadequately controlled on metformin monotherapy.  
Vildagliptin produced a statistically significant and clinically meaningful 
change in HbA1c compared with placebo (-1.1% vs. -0.1%; P\0.001) as add-on to 
metformin (250 mg bid or 500 mg bid) after 12 weeks of treatment in Japanese patients 
with T2DM. 
A similar result was obtained from Pan et al., adding vildagliptin to metformin 
resulted in 1.05% reduction of HbA1C after 24 weeks treatment. In a recent Indian 
retrospective study Chatterjee et al., the reduction in HbA1C was 1.9% which is 
compatible with another study Bosi et al., where vildagliptin combined with metformin 
was given in treating T2DM naïve patients. 
The similar results shows that Ahren et al., combination of vildagliptin therapy 
with metformin have also been evaluated in three double-blind controlled studies and 
showed statistically meaningful reduction in Hba1c of 0.7 and 0.9%. A meta-analysis 
Cail et al., of 30 randomized controlled trials showed that treatment with vildagliptin, 
metformin and sulfonylurea are decreased Hba1c by 0.77%. 
Post 3 months of treatment for the two groups are shown below. The mean 
HbA1c of the dual therapy for group -A (teneligliptin with metformin) was 7.1±0.5% 
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and group C (Vildagliptin with metformin) therapy 7.9±0.75% .The mean HbA1c of 
combination therapy was found to be (teneligliptin with metformin plus sulfonylurea) 
7.49±0.48%, which was significantly lower than the mean HbA1c in 8.60±0.48%   in 
group C (Vildagliptin with metformin plus sulfonylurea) therapy. In this study it is 
clearly evident that Group -A (dual and combination therapy) patients had greater 
reduction in HbA1c level when compared to Group C (dual and combination therapy). 
This fact is supported by the study conducted by Tushar et al.in which finally 
concluded that teneligliptin therapy is more effective than vildagliptin therapy. 
In group A the mean FBS of dual therapy (teneligliptin with metformin) 
was123.62±9.31mg/d L which was significantly lower than the mean FBS in 
142.89±21.10mg/d L in group C (Vildagliptin with metformin) therapy.In group A the 
mean FBS of combination therapy (teneligliptin with metformin plus sulfonylurea) was 
121.5±22.69mg/d L, which was significantly lower than the mean FBS in 
132.9±25.07mg/d L in group C (Vildagliptin with metformin plus sulfonylurea) 
therapy. 
It is shows Group A (dual and combination therapy) patient had greater 
reduction of FBS than compared to Group C (dual and combination therapy). The 
similar result shows that the study conducted Tushar et al., in which finally concluded 
that teneligliptin therapy is more effective than vildagliptin therapy. 
In group A the mean PPBS of dual therapy (teneligliptin add on metformin) was 
164.16±35.15mg/d L which was significantly lower than the mean PPBS in 
190.44±29.29mg/d L mg/d L in group C (Vildagliptin add on metformin) therapy. 
In group A the mean PPBS of combination therapy (teneligliptin add on 
metformin plus sulfonylurea) was 183.44±19.84mg/d L which was significantly lower 
than the mean PPBS in 199.49±21.80mg/d L in group C (Vildagliptin add on metformin 
plus sulfonylurea) therapy. 
It is clearly evident that Group A (dual and combination therapy) patient had 
greater reduction of PPBS than compared to Group C (dual and combination therapy). 
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The similar result shows that the study conducted Tushar et al., finally concluded that 
teneligliptin therapy is more effective than vildagliptin therapy. 
A mean reduction in HbA1C of 7.1±0.5%, was seen with teneligliptin add on 
metformin therapy, while a same mean reduction in HbA1c of 7.1±0.5% was found 
with sitagliptin add on metformin therapy. Comparison both the groups demonstrated 
that there was no significant difference. 
Mean reduction in HbA1C of 7.49±0.48% was seen with teneligliptin with 
metformin plus glimepiride therapy, while a slight increase of HbA1c of 7.51±0.54% 
was found with sitagliptin add on metformin plus glimepiride therapy. Comparison both 
the groups demonstrated that there was no significant difference. 
Which was similar to the study conducted Eto et al., Mean reduction of HbAIC 
in teneligliptin therapy, and was same to the mean reduction of sitagliptin therapy. But 
Wakaba Tsuchimochi et al., study shows that teneligliptin is more effective than 
sitagliptin therapy because of the structural advantages of teneligliptin. 
A mean reduction in FBS of 123.6±9.31mg/d L was seen with teneligliptin with 
metformin therapy, while a same mean reduction in FBS of 123.64±20.24mg/d L was 
found with sitagliptin with metformin therapy. Comparison both the groups 
demonstrated that there was no significant difference. 
A mean reduction in FBS of 121.5±22.69mg/d L was seen with teneligliptin add 
on metformin plus glimepiride therapy, while a slight decrease of FBS of 
121.41±19.96mg/d L was found with sitagliptin add on metformin plus glimepiride 
therapy. 
Which was similar to the study conducted Eto et al., mean reduction of FBS in 
teneligliptin therapy, was equaling to the mean reduction of sitagliptin therapy. But 
Wakaba Tsuchimochi et al., study shows that teneligliptin is more effective than 
sitagliptin therapy because of the structural advantages of teneligliptin. 
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Mean reduction in PPBS of 164.1±35.15mg/d L, was seen with teneligliptin add 
on metformin therapy, while a same mean reduction in PPBS of 164.1±30.16mg/d L 
was found with sitagliptin add on metformin therapy. On the comparison both the group 
demonstrated no difference statistically. 
A mean reduction in PPBS of 183.44±19.84mg/d L, was seen with teneligliptin 
add on metformin plus glimepiride therapy, while a same mean reduction in PPBS of 
183.9±20.65mg/d L was found with sitagliptin add on metformin plus glimepiride 
therapy. 
Which was similar to the study conducted Eto et al., mean reduction of PPBS 
in teneligliptin therapy, was equality to the mean reduction of sitagliptin therapy. But 
Wakaba Tsuchimochi et al study shows that teneligliptin is more effective than 
sitagliptin therapy because of the structural advantages of teneligliptin. 
On the comparison both the group demonstrated no difference statistically. It 
shows that both the regimens on comparison reveled similar efficacy there by failing to 
prove the superiority over each other. 
In this study there was no significance difference between SrCr following 3 
months of therapy with teneligliptin and its combinations when compared with 
sitagliptin and its combinations and vildagliptin and its combinations. SGPT level 
showed a slightly significant increase in three groups, but which was still in normal 
range. The result of this study perfectly complies with the former study conducted by, 
Manish Maladkar et al., his study shows that gliptins do not causes any reanal and 
hepatic impairment. 
Treatment with Teneligliptin and its combination was well tolerated over the 3 
months treatment period. In monotherapy there were no ADR reported. In combination 
therapy 8 patients experienced ADRs. Mild hypoglycemia reported in (6%) the cases, 
was mostly reported ADR followed by GI irritation (8%) and less in headache (2%). 
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Awadhesh Kumar Singh et al., observed that in monotherapy only <1% of 
ADRs were occurred. In combination therapy hypoglycemia, GI irritation, head ache, 
peripheral edema and nasopharangytis were occurred. 
There were no severe ADR was found in Sitagliptin and its combination therapy 
.Mild GI irritation (12%) was occurred in the group. Other ADR including nausea (2%) 
and headache (2%) and diarrhea (4%) were happened among the group. Supporting to 
this study Jennifer Green et al., in her study didn’t shown any hypoglycemic events 
in sitagliptin therapy and GI irritation, nausea and headache were found. 
The frequent ADR in the vildagliptin and their combination therapy were 
hypoglycemia (14%)   GI irritation (8%), headache (4%), dizziness (2%) and diarrhea 
(2%).  
Which was similar to the study conducted by Yun‑Zhao Tang et al., in his the 
ADR of vildagliptin therapy shows more in hypoglycemia (18.9%) and GI irritation 
(16.6%). 
The cost effectiveness of teneligliptin, sitagliptin, and vildagliptin monotherapy 
and their combination with metformin was studied. It shows that teneligliptin and its 
combination with metformin was found to be more cost effective. This fact is supported 
by the study conducted by Ghosh et al., his study shows that teneligliptin is 
economically effective compared with other gliptins. 
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8. CONCLUSION 
Out of 150 patients, the prevalence of type 2 diabetes mellitus was higher in 
males than females in age group of 51-60 years and most of the patients were observed 
in the duration was 0-5 years. From this study it was observed that only female patients 
having the comorbid conditions were thyroid and rheumatoid arthritis. 
This study provides an evidence of safety and efficacy of teneligliptin as a 
monotherapy or in combination therapies with a Metformin and Glimepiride in patients 
with type II Diabetes mellitus. 
The results pointed out that all the group  of patients showed an improvement 
in their glycemic parameters such as FBS, PPBS, and HbA1c during the study period 
and from the group comparison study it was observed that the patients receiving 
combination therapy of teneligliptin have better glycemic control than combination 
therapy of vildagliptin.  
The study demonstrated the effectiveness of teneligliptin combination and 
sitagliptin combination therapy in type II diabetes mellitus patients. Both the 
combinations on comparison reveled similar efficacy in glycemic parameter, there by 
failing to prove the superiority in over each other. 
There was no significance difference was found in SrCr and SGPT level for the 
follow-up of 3 months  therapy with teneligliptin  combinations,  sitagliptin 
combinations and vildagliptin combinations. 
No severe ADR were reported in the 3 groups. All the ADR reported during the 
study were mild. However the incidence of ADR were numerically more in vildagliptin 
combination therapy and the incidence of hypoglycemia is more in sitagliptin 
combination therapy. The teneligliptin combination shows lesser side effects than the 
other two combinations. Vildagliptin group shows ADR like GI irritation, 
Hypoglycemia, Headache and Dizziness. In that occurrence of hypoglycemia were high 
and other ADRs were mild. Sitagliptin groups shows ADRs like GI irritation, head 
ache, nausea and diarrhea, in that the major ADR was GI irritation. Compare to the 
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other two groups of combination drugs, teneligliptin has less ADRs like GI irritation, 
Hypoglycemia and Diarrhea. There was no incidence of renal and hepatic toxicity with 
all the three combination drugs. 
The cost effective analysis of teneligliptin, sitagliptin, and vildagliptin 
monotherapy and their combination with metformin was done , the results shows that 
teneligliptin alone and its combination with metformin was found to be more cost 
effective than the other groups of drugs. 
The teneligplin has more advantages than the other two gliptins in type II 
diabetes mellitus patients. Teneligliptin with metformin and sulfonyl urea treatment 
was effective and well tolerated in patients with type II diabetes and it has long half-
life of 26.9 hours with unique pharmacokinetic advantage which allows convenient 
once daily administration irrespective of food. It has dual mode of elimination via renal 
and hepatic, hence it can be administered safely in renal impairment patients. No dosage 
adjustment is required in mild to moderate hepatic impairment. The appropriate 
approach towards managing diabetes should be not only glycemic control but also 
preservation of islet cell function early and to delay the progression of a disease. 
In conclusion teneligliptin significantly improves glycemic parameters in Indian 
T2DM patients with mild ADRs when prescribed as monotherapy or as add-on to 
Metformin and Sulfonyl ureas and it also cost effective than the other gliptins. 
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KOVAI MEDICAL CENTER AND HOSPITAL - COIMBATORE 
DATA COLLECTION FORM 
       Date:                                                                                                   IP No: 
       Name:                                                                 Age:                        Sex: M/F 
 Height:                                                               Weight:                    BMI: 
 Marital status:  Married                                  Single   
Social habits:   Smoker                                     Alcoholic 
Past history:     Jaundice                      Pancreatitis                 Rhinitis               Others 
Family history:  Diabetes Mellitus:  Yes                          No  
       Co-exiting illness: Thyroid                     Rheumatoid Arthritis                       Others 
       Duration of type II Diabetes Mellitus:   0-5 years              6-10 years             >10 years 
 LAB INVESTIGATIONS 
 
 
 
Parameter 
Teneligliptin Sitagliptin Vildagliptin 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
FBS( mg/dl)       
PPBS (mg/dl)       
HbA1C (gm %)       
SrCr (mg/dl)       
SGPT( IU/L) 
 
      
  
  
    
  
   
   
 TREATMENT CHART: 
Sl.no Drug name Price/tablet Dose Freequency 
1. Teneligliptin Rs. 7 
20 mg Once a day  
 
2. Sitagliptin Rs. 42 
25mg/ 50mg/ 
100mg 
         Twice a day 
   3. Vildagliptin Rs.19.28 50mg/ 100mg          Twice a day 
 
  
    ADVERSE DRUG REACTIONS OF TENELIGLIPTIN 
Hypoglycemia Yes                                              No   
Constipation Yes                                              No   
Nasopharyngitis Yes                                              No   
Proteinuria Yes                                              No   
Ketonuria Yes                                              No   
Glucosouria Yes                                              No   
ECG abnormality 
(QT prolongation) 
Yes                                              No   
Others  Yes                                              No   
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Second line:       Yes                                               No 
Third line:          Yes                                              No  
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ADVERSE DRUG REACTIONS OF SITAGLIPIN 
Nasopharyngitis Yes                                              No   
Hypoglycemia Yes                                              No   
Constipation Yes                                              No   
Diarrhea Yes                                              No   
UTI Yes                                              No   
Upper respiratory tract infection Yes                                              No   
Peripheral edema Yes                                              No   
Others  Yes                                              No   
 
ADVERSE DRUG REACTIONS OF VILDAGLIPIN 
Dizziness Yes                                              No   
Pancreatitis Yes                                              No   
Constipation Yes                                              No   
Head ache Yes                                              No   
UTI Yes                                              No   
Hypoglycaemia Yes                                              No   
Osthers Yes                                              No   
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OTHER ANTIDIABETIC DRUGS: 
Category Name of drug Price Dose Freequency 
Oral anti diabetic 
drugs 
    
Sulfonylurea     
Glitazones     
Biguanide     
∝-glucosidase inhibitor     
 
ADVERSE DRUG REACTIONS OF OTHER ANTIDIABETIC DRUGS: 
Hypoglycaemia Yes                                              No   
Nausea Yes                                              No   
Hyponatremia  Yes                                              No   
Lactic acidosis Yes                                              No   
Renal insufficiency Yes                                              No   
Liver disease Yes                                              No   
Metallic taste Yes                                              No   
Diarrhea Yes                                              No   
Weight gain Yes                                              No   
Fluid retention Yes                                              No   
Heart failure Yes                                              No   
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